Considerations of red blood cell molecular testing in transfusion medicine

Expert Review of Molecular Diagnostics

Volumn 15, Issue 11, 2015, Pages 1455-1464

  Svensson, Annika M ^a,b   Delaney, Meghan ^c,d,e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Children's Hospital Colorado   (United States)

^c BloodWorks Northwest   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

blood transfusion; hemolytic disease of the fetus and newborn; immunohematology; red cell genotyping; red cell serology

Indexed keywords

AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD BANK; BLOOD GROUP; BLOOD GROUP GENOTYPING; BLOOD GROUP RHESUS SYSTEM; BLOOD GROUP TYPING; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FETUS; GENOTYPE; GOLD STANDARD; HEMOLYTIC ANEMIA; HUMAN; NEWBORN; REVIEW; SEROLOGY; SICKLE CELL ANEMIA; THALASSEMIA; TRANSFUSION MEDICINE; BLOOD EXAMINATION; CLASSIFICATION; GENETICS; GENOMICS; GENOTYPING TECHNIQUE; IMMUNOLOGY; METABOLISM; MOLECULAR DIAGNOSIS; PROCEDURES;

BLOOD GROUP ANTIGEN;

BLOOD GROUP ANTIGENS; BLOOD GROUPING AND CROSSMATCHING; ERYTHROCYTES; GENOMICS; GENOTYPING TECHNIQUES; HEMATOLOGIC TESTS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; TRANSFUSION MEDICINE;

EID: 84947125682     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1086646     Document Type: Review

References (66)

1. Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. 3rd edition Elsevier; 2012
2. Daniels G. Human Blood Groups. 3rd edition Wiley; 2013
3. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008; 112: 2546-53
4. International society of blood transfusion. Available from: www. isbtweb.org. [Last accessed 20 July 2015]
5. Patnaik SK, Helmberg W, Blumenfeld OO. BGMUT: NCBI dbRBC database of allelic variations of genes encoding antigens of blood group systems. Nucleic Acids Res 2012; 40: D1023-9
6. Denomme GA. Molecular basis of blood group expression. Transf Apher Sci 2011; 44: 53-635
7. Okuda H, Suganuma H, Kamesaki T, et al. The analysis of nucleotide substitutions, gaps, and recombination events between RHD and RHCE through complete sequencing. Biochem Biophys Res Commun 2000; 274: 786-94
8. Colin Y, Cherif-Zahar B, Le Van Kim C, et al. Genetic basis of the RhD-positive and RhD negative blood group polymorphism as determined by Southern analysis. Blood 1991; 78: 2747-52
9. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in most Africans with the RhD-negative blood group phenotype. Blood 2000; 95: 12-18
10. Daniels GL, Faas BHW, Green CA, et al. The VS and V blood group polymorphisms in Africans: a serologic and molecular analysis. Transfusion 1998; 38: 951-8
11. Avent ND, Reid ME. The Rh Blood group system: a review. Blood 2000; 95: 375-87
12. Asfour M, Narvios A, Lichtiger B. Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients. MedGenMed 2004; 6: 22
13. Westhoff CM. The structure and function of the Rh antigen complex. Semin Hematol 2007; 44: 42-50
14. Flegel WA, Wagner FF. RHD epitope density profiles of RHD variants red cells analyzed by flow cytometry. Transfus Clin Biol 1996; 3: 429-31
15. Wagner FF, Gassner C, Müller TH, et al. Molecular basis of weak D phenotypes. Blood 1999; 93: 385-93
16. Wagner FF, Frohmajer A, Ladewig B, et al. Weak D alleles express distinct phenotypes. Blood 2000; 95: 2699-708
17. Wagner FF, Kasulke D, Kerowgan M, et al. Frequencies of the blood groups ABO, Rhesus, D category IV, Kell, and of clinically relevant high-frequency antigens in South-Western Germany. Infusionsther Transfusionsmed 1995; 22: 285-90
18. RhesusBase. Available from: www.uni-ulm.de/∼fwagner/RH/RB2
19. Daniels G. Variants of RhD-current testing and clinical consequences. Br J Haematol 2013; 161: 461-70
20. Flegel WA, Denomme GA. Allo-and autoanti-D in weak D types and in partial D. Transfusion 2012; 52: 2068-9
21. Pham BN, Roussel M, Peyrard T, et al. Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo-or autoantibodies? Transfusion 2011; 51: 2679-85
22. Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004; 8: 23-31
23. Van der Schoot CE, Soussan AA, Koelewijn J, et al. Non-invasive antenatal RHD typing. Transfus Clin Biol 2006; 13: 53-7
24. Gautier E, Benachi A, Giovangrandi Y, et al. Fetal Rh D genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol 2005; 192: 666-9
25. Minon J-M, Gerard C, Senterre J-M, et al. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion 2008; 48: 373-81
26. Legler J, Damme S, Müller S. The German feasibility study on non-invasive determination of the fetal D-status from maternal plasma for decision making on RH-prophylaxis. Vox Sang 2007; 93 (Suppl 1): 53
27. de Haas M, Finning K, Massey E, et al. Anti-D prophylaxis: past, present and future. Transfus Med 2014; 24: 1-7
28. Goodnough LT, Daniels K, Wong AE, et al. How we treat: transfusion medicine support of obstetric services. Transfusion 2011; 51: 2540-8
29. Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D-pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012; 52: 752-8
30. Brajovich ME, Boggione CT, Biondi CS, et al. Comprehensive analysis of RHC alleles in Argentineans with variant D phenotypes. Transfusion 2012; 52: 389-96
31. Sandler SG, Roseff S, Domen RE, et al. For the college of american pathologists transfusion medicine resource committee. Arch Pathol Lab Med 2014; 138: 620-5
32. Sandler SG, Flegel WA, Westhoff CM, et al. College of american pathologists transfusion medicine resource committee work group. its time to phase in rhd genotyping for patients with a serologic weak d phenotype. college of american pathologists transfusion medicine resource committee work group. Transfusion 2015; 55: 680-9
33. Kacker S, Vassallo R, Keller MA, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion 2015. [Epub ahead of print]
34. Bennett PR, Le Van Kim C, Colin Y, et al. Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med 1993; 329: 607-10
35. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-7
36. Lo YM, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339: 1734-8
37. Faas BH, Beuling EA, von Christiaens GC, et al. Detection of fetal RHD-specific sequence in maternal plasma. Lancet 1998; 352: 1196
38. Avent ND. RHD genotyping from maternal plasma: guidelines and technical challenges. Methods Mol Biol 2008; 444: 185-201
39. Lee MT, Piomelli S, Granger S, et al. For the STOP Study Investigators. Stroke prevention trial in sickle cell anemia [STOP]: extended follow-up and final results. Blood 2006; 108: 847-52
40. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312: 1033-48
41. Evidence-based management of sickle cell disease. Avaibale from www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report.pdf. [Last accessed 15 June 2015]
42. Chou S, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-71
43. Yazdanbaksch K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120: 528-37
44. Vichinsky EP, Luban NL, Wright E, et al. Stroke Prevention Trial in Sickle Cell Anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-92
45. Godfrey GJ, Lockwood W, Kong M, et al. Antibody development in pediatric sickle cell patients undergoing erythrocytapheresis. Pediatr Blood Cancer 2010; 55: 1134-7
46. Tournamille C, Meunier-Costes N, Coste B, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. Transfusion 2010; 50: 13-19
47. Pham B-N, Peyrard T, Tourret S, et al. Anti-HrB and anti-hrB revisited. Transfusion 2009; 49: 2400-5
48. Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43
49. Monteiro F, Tavares G, Ferreira M, et al. Technologies involved in molecular blood group genotyping. ISBT Science Series 2011; 6: 1-6
50. Peyrard T. Molecular tools for investigating immunohaematology problems. ISBT Science Series 2015; 10: 31-8
51. LaSalle-Williams M, Nuss R, Cole L, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center. Transfusion 2011; 51: 1732-9
52. Global distribution of haemoglobin disorders, in terms of births of affected infants per1000 births. Available from: www.who.int/genomics/public/Maphaemoglobin.pdf. [Last accessed 20 June 2015]
53. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011; 118: 3479-88
54. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000; 96: 3369-73
55. Thompson AA, Cunningham MJ, Singer ST, et al. For the thalassemia clinical research network investigators. red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 2011; 153: 121-8
56. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012; 159: 394-404
57. Evaluating people with thalassemia: the thalassemia longitudinal cohort (TLC) Study. Available from: https://clinicaltrials.gov/ct2/show/NCT00661804
58. Hussein E, Desooky N, Rihan A, et al. Predictors of Red Cell Alloimmunization in Multitransfused Egyptian Patients With b-Thalassemia. Arch Pathol Lab Med 2014; 138: 684-8
59. Lannan KL, Sahler J, Spinelli SL, et al. Transfusion immunomodulation-the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis 2013; 50: 61-8
60. Spinella PC, Dressler A, Tucci M, et al. Survey of transfusion policies at US and Canadian childrens hospitals in 2008 and 2009. Transfusion 2010; 50: 2328-35
61. Olsson ML, Chester MA. Polymorphism and recombination events at the ABO locus: a major challenge for genomic ABO blood grouping strategies. Transfus Med 2001; 11: 295-313
62. Hosseini-Maaf B, Hellberg A, Chester MA, et al. An extensive polymerase reaction-allele-specific polymorphism strategy for clinical ABO blood group genotyping that avoids potential errors caused by null, subgroup, and hybrid alleles. Transfusion 2007; 47: 2110-25
63. Cho D, Lee JS, Yazer MH, et al. Chimerism and mosaicism are important causes of ABO phenotype and genotype discrepancies. Immunohematol 2006; 22: 183-7
64. Lomas-Francis C. Blood Group Genetics. In: Fung MK, Grossman BJ, Hillyer C, Westhoff CM.,. editors. Technical manual. 18th edition. Bethesda, MD: 2014
65. Daniels G. Variants of RhD-current testing and clinical consequences. Br J Haematol 2013; 161: 461-70
66. Cassas J, Friedman DF, Jackson T, et al. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 2015; 55: 1388-93